Findings

What do systematic reviews say?

1,501 questions · 1,558 findings · 115 reviews · Vascular

Sort:Best matchNewestHighest certainty Download CSV

No studies found 346 · 22.2%GRADE not reported 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%

Nitrate/nitrate derivatives vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 77 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nitrate/nitrate derivatives vs placebo

Adverse events (3 weeks' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 69 participants
Low

Phosphodiesterase inhibitors vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Low

Phosphodiesterase inhibitors vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Very low

Phosphodiesterase inhibitors vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

Adverse events · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 138 participants
GRADE not reported

Phosphodiesterase inhibitors vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Adverse events (4 to 6‐week · primary Raynaud's phenomenon

Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.35 [0.67, 2.73]
3 studies · 46 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alpha‐blockers vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Alpha‐blockers vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
GRADE not reported

Alpha‐blockers vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Slow vs fast subcutaneous heparin injection

Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 140 participants
Low

Slow vs fast subcutaneous heparin injection

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 103 participants
Low

Slow vs fast subcutaneous heparin injection

Bruise size 48 hours after injection (mm/mm2) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 503 participants
Very low

Slow vs fast subcutaneous heparin injection

Bruise size ‐ 60 hours after injection (mm2) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 84 participants
Low